Preclinical epigenetic models for screening epigenetic drugs for schizophrenia
1Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, India.
Abstract:
Schizophrenia is an important psychiatric disorder for which effective drugs are available. However, there are problems with current drug therapy of schizophrenia in that some patients do not respond adequately. Moreover, some patients show treatment resistance and some patients show cognitive decline despite treatment. Hence new and effective drugs will be useful for the treatment of this disorder. Since there is increasing evidence that epigenetic mechanisms of gene expression are defective in schizophrenia, drugs that correct epigenetic defects, epigenetic drugs, could be useful in the treatment of this disorder. This paper discusses preclinical epigenetic models for screening epigenetic drugs for schizophrenia. It also discusses how such models could be useful for the discovery and development of such drugs.
Related Concept Videos
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Psychological and Sociocultural Causes of Schizophrenia
EPS and iPS Cells in Disease Research


